Listed by the USPTO as HENLEY III, RAYMOND J
Tech Center 1600 • Art Units: 1614 1629 1652
This examiner grants 84% of resolved cases
Raymond J. Henley III handles cases in Tech Center 1600 and Art Unit 1614. He has resolved 1258 cases with an allowance rate of 83.5%. The median days to allowance is 694, suggesting a relatively efficient path to grant for successful applications. This pendency of 694 days is a primary metric for applicants in his docket.
The interview lift is 2.3%, showing a minimal change in allowance outcomes after conducting an interview compared to the 83.5% allowance rate. With an 83.5% allowance rate already in place, the marginal benefit of an interview appears limited. Veradermics Incorporated is a top company in his portfolio, and Procopio, Cory, Hargreaves & Savitch LLP is a primary firm. Practitioners should weigh the 2.3% lift against the high baseline probability of success when determining their prosecution strategy. The 1258 resolved cases provide a robust data set for predicting future outcomes. Efficiently navigating the 694-day median timeline should be a priority for applicants seeking to join the 83.5% of allowed cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19572667 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19572691 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19569918 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19569963 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19570012 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19546257 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19546276 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19542655 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19539689 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19538689 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19538745 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19449371 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19447910 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19445410 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19444686 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19445445 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19443936 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19442899 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19442979 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19427815 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19420555 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19402812 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19397854 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19329476 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19329494 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19328077 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19308124 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19303300 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19267464 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
| 19267447 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Non-Final OA | Veradermics, Incorporated |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy83.5% of resolved applications examined by Raymond J Henley III were allowed (1,258 resolved cases), compared with 47.9% across Art Unit 1614 over the last five years.
This examiner's interview lift is +2.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Raymond J Henley III took 694 days on average from filing to allowance.
Raymond J Henley III examines applications in Art Unit 1614 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
